Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Procrit Could Return To Growth Later This Year, J&J Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Anemia therapy should reverse a quarterly sales decline brought on by competition from Amgen, Johnson & Johnson maintains. Worldwide sales were up for the second quarter.

You may also be interested in...



Procrit Critical Care Label Expansion Could Fuel Franchise Sales, J&J Says

Johnson & Johnson remains committed to the anemia agent despite failing to return the franchise to growth in 2005.

Procrit Critical Care Label Expansion Could Fuel Franchise Sales, J&J Says

Johnson & Johnson remains committed to the anemia agent despite failing to return the franchise to growth in 2005.

J&J Expects EPO Pricing Injunction Ruling In Early 2006

If the court fails to grant a preliminary injunction against Amgen, "tremendous price pressure" will be reinjected into the EPO market, the Procrit marketer tells analysts.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel